In this week’s Trending News EU episode, Jack, Ollie, and Will discuss a few recent newsworthy items on UK Life Sciences policy including what the latest spring budget means for Life Sciences (1.00), future pricing of branded medicines in the UK and differences with other countries (6.10), and how Life Sciences policy is working to attract investment and talent to the UK (18.55).

Podcast Tags: healthcare, healthcare news, NHS, life sciences policy, healthcare policy, government budget, life sciences, brexit, life sciences regulation, healthcare regulation, medicine pricing, VPAS, healthcare costs, healthcare investment

Source Links:

Spring Budget 2023 (HTML) - GOV.UK (www.gov.uk)

MHRA to receive £10m from HM Treasury to fast-track patient access to cutting-edge medical products - GOV.UK (www.gov.uk)

Chancellor gives boost to medical innovation and life sciences industry in Spring Budget | BIA (bioindustry.org)

ABPI response to the Budget

Industry reacts to approvals and R&D tax credit changes in Budget - Med-Tech Innovation (med-technews.com)

Voluntary Scheme on branded medicines (abpi.org.uk)

Comparing International Prescription Drug Prices | RAND

Leading global pharma firms exit UK drug pricing agreement (abpi.org.uk)

Life Sciences Innovative Manufacturing Fund (LSIMF) (closed to Expressions of Interest) - GOV.UK (www.gov.uk)

Life sciences companies supercharged with £277 million in government and private investment - GOV.UK (www.gov.uk)

UK government, private investors dole out $340M+ to drug, diagnostic manufacturers – Endpoints News (endpts.com)

For additional discussion, please contact us at TrendingHealth.com or share a voicemail at

1-888-VYNAMIC.

Jen Burke, Director

Jen.Burke@vynamic.com

Jack Young, Director

jack.young@vynamic.com

Oliver May, Senior Manager

oliver.may@vynamic.com

Will Turnbull, Senior Manager

Will.turnbull@vynamic.com